Avalia Immunotherapies collapses, owes $1m to Callaghan Innovation

Avalia Immunotherapies collapses, owes $1m to Callaghan Innovation
Dr Shivali Gulab, CEO of Avalia Immunotherapies. (Image: Avalia)
Riley Kennedy
Liquidators have been appointed to a biotech outfit that helped produce a covid-19 vaccine after it failed to raise cash to help further its other project.Founded in 2015, Avalia Immunotherapies was a preclinical-stage biotech company attempting to develop a fully synthetic vaccine and immunotherapy platform. Its lead programme was targeting a functional cure for chronic Hepatitis B.After it couldn’t raise further funding for clinical development, Baker Tilly Staples Rodway’s Tony Maginness and Jared Booth were appointed liquid...

More Finance

Westpac NZ calls on Google and Meta to do more
Finance

Westpac NZ calls on Google and Meta to do more

CEO says Google, Meta's effort are "piecemeal'"

Andy Macdonald 03 Nov 2025
Baker's dozen: Westpac NZ hikes FY profit by 13%
Finance

Baker's dozen: Westpac NZ hikes FY profit by 13%

Lift for bank's NZ arm comes as Aussie parent sees its bottom line slip. 

Andy Macdonald 03 Nov 2025
Could your KiwiSaver soon own your local water system?
Finance

Could your KiwiSaver soon own your local water system?

Founder Sam Stubbs says 90% of Kiwis back the idea of owning local utilities.

Garth Bray 03 Nov 2025
Big names for Wellington Water board
Finance

Big names for Wellington Water board

Credit rating agency warns that water reforms are no council debt panacea.

Pattrick Smellie 31 Oct 2025